A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors

Anti-Cancer Drugs

Volumn 18, Issue 5, 2007, Pages 587-595

  Rasschaert, Marika ^a,b   Schrijvers, Dirk ^b   Van Den Brande, Jan ^a   Dyck, Joke ^a   Bosmans, Johan ^a   Merkle, Karlheinz ^c   Vermorken, Jan B ^a,d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c Clinical Research Unit   (Germany)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

Bendamustine; Day 1 every 3 weeks schedule; Phase I; Solid tumors

Indexed keywords

BENDAMUSTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; FLUORESCENCE ANALYSIS; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SHORT COURSE THERAPY; SIDE EFFECT; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; TACHYCARDIA; THROMBOCYTOPENIA; THYROID CANCER; URINARY TRACT CANCER; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS;

EID: 34247093863     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280149eb1     Document Type: Article

References (35)

1. Ozegowski W, Krebs D. w-[bid-(β-chlorethyl)-amino-benzimazolyl-(2)]- propionic or butyric acids as potential cytotoxic agents. J Prakt Chem 1963; 20:178-186.
2. Gandhi V. Metabolism and mechanisms of action of Bendamustine: rationale for combination therapies. Semin Oncol 2002; 29 (Suppl 13):4-11.
3. Barmam Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61:631-640.
4. Strumberg D, Harstrick A, Doll K, Hoffman B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-cancer Drugs 1996; 7:415-421.
5. Leoni LM, Bailey B, Reiffert J, Niemeyer C, Bendall H, Dauffenbach L, Kerfoot C. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 2004; 45:[Abstract 1215].
6. Niemeyer C, Bailey B, Reiffert FJ, Bendall H, Corbeil J, Leoni LM. SDX-105 (Bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action. Proc Am Assoc Cancer Res 2004; 45: [Abstract 1129].
7. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR. Cytotoxic efficacy of bendamustine in human leukaemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002; 128:271-278.
8. Schwänen C, Hecker T, Hübinger G, Wölfe M, Rittgen W, Bergmann L, Karakas T. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002; 16:2096-2105.
9. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoezer D, Mitrou PS, Weidmann E. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001; 86:485-493.
10. Chow KU, Nowak D, Boeher S, Ruthardt M, Knau A, Hoelzer D, et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003; 66:711-724.
11. Preiss R, Sohr R, Matthias M, Brockmann B, Hüller H. Untersuchungen zur Pharmakokinetik von Bendamustine (Cytostasan) am Menschen. Pharmazie 1985; 40:782-784.
12. Bräunlich H, Stolze G, Stolze R. Renale wirkungen von Bendamustin (Cytosan®) bei Ratten. Pharmazie 1998; 43:265-268.
13. 1-Mäusen. Pharmazie 1991; 46:589-591.
14. Bezek S, Scasnár V, Trnovec T, Grupe R. Hepatobiliary elimination of bendamustin (Cytosan®) in rats. Pharmazie 1991; 46:810-811.
15. Güttner J, Burns G, Juingstand W. Onkogene Wirkung von χ-[1-Methyl-5-bis-(β-chloräthyl)-aminobenzimidazolyl-(2)] -buttersäuerhydrochlorid (Cytostasan®) bei der Maus. Arch Geschulstforsch 1974; 43:16-21.
16. Heinecke H, Klaus S. Embryotoxic and teratogenic action of the nitrogen mustard derivatives IMET 3393 and IMET 3106 in micer. Zentralbl Pharm Pharmacother Laboratoriumdiagn 1971; 110:1067-1076.
17. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002; 29:27-32.
18. Cohen P, Cheson B, Friedberg J, Robinson KS, Foran J, Fayad L, et al. The novel alkylator, Trenada™ (Bendamustine HCl), is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity. Proc Am Soc Clin Oncol 2005; 23 (Suppl 16):576s [Abstract 6564].
19. Borchmann P, Schnell R, Diehl V, Engert A. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998; 9 (Suppl 5):S103-S108.
20. Avaido M, Schulte K, Henze LM, Burger J, Finke J, Haas R Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002; 29 (Suppl 13):S19-S22.
21. Knauf WU, Lissitchkov T, Herbrecht R, Loscertales J, Aldaoud A, Merkle K. Bendamustine versus chlorambucil in treatment - naïve B-CLL patients. Blood 2004; 104:287b [Abstract 4817].
22. Pönisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol 2002; 29 (Suppl 13):S23-S26.
23. Ponisch W, Mitrou PS, Merkle K, Hrold M, Assmann M, Wilhelm G, et al. Treatment of Bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132:204-212.
24. Reck M, Haering B, Koschel G, Kaukel E, Van Pauwel J, Gatzemeier U. Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelligen Bronchialkarzinoms mit Bendamustin- Eine Phase II Studie. Pneumologie 1998; 52:571-574.
25. Koester W, Stamatis G, Niederle N, Heider A, Avramidis K, Wilke H, et al. Phase II study with bendamustine/carboplatin in untreated patients with extensive disease small cell lung Cancer. J Clin Oncol 2004; 22:7265.
26. Höffken K, Merkle KH, Schönfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998; 124:627-632.
27. Zulkowski K, Kath R, Semrou R, Merkle K, Höffken K. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 2002; 128:111-113.
28. von Mickwitz G, Chermozemsky I, Sirakova L, Chilingrirov P, Souchon R, Marschner N, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16:871-877.
29. Kollmannsberger C, Gerl A, Scheuler N, Beyer J, Kuczyk M, Rick O, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 2000; 11:535-539.
30. Schöffski P, Seeland G, Engel H, Grünwald V, Paul H, Merkle K, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumors. Ann Oncol 2000; 11:729-734.
31. Schöffski P, Hagedorn T, Grünwald V, Paul H, Merkle K, Kowalski R, et al. Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumors. J Cancer Res Clin Oncol 2000; 126:41-47.
32. Matthias M, Preiss R, Sohr R, Possinger K. Pharmacokinetics of bendamustine in patients with malignant tumors. Proc Am Soc Clin Oncol 1995; 14:485 [Abstract 1476].
33. Teichert J, Baumann F, Chao Q, Franklin C, Bailey B, hennig L, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2006; [Epub ahead of print].
34. Teichert J, Mockel J, Pönisch W, Seidel A, Lotfi M, Matthias M, et al. Influence of hepatic and renal function on the pharmacokinetics of bendamustine. Int J Clin Pharmacol Ther 2003; 41:564.
35. Teichert J, Sohr R, Baumann F, Henning L, Merkle K, Caca K, et al. Synthesis and characterisation of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005; 33:984-992.